· Phase I: CRAd by IP safe, 60% SD [196].· Phase I: DNX-2401 by ITu administration in glioma safe, 12% CR rate, 11 months OS [199]· Phase I: DX-2401 or Ad5-D24-RDG-GMCSF ITu in solid tumors safe, 27% with SD [197].· Phase I: CGTG-102 ITu in sarcoma safe, 75% with SD [198]. CGTG-102 ITu in solid tumors plus oral low-dose cyclophosphamide safe, 40% with controlled disease at 3 months [172].· ColoAd1 has low level of pre-existing host immunity [200] and potentially higher potency than ONYX-015 [201]. It is tested in a mechanism of action Phase I study [202]. The gene discussed is CSF2; the disease is glioma.